Label: SALKALLI- retatrutide lyophilized powder injection, powder, lyophilized, for solution

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Export only

Drug Label Information

Updated November 7, 2025

If you are a consumer or patient please visit this version.

  • Active ingredients (in each kit)

    Retatrutide 2.5 mg (lyophilized powder)

    Sterile Water for Injection 0.25 mL

  • Purpose

    Antidiabetic / Weight management agent

    Diluent

  • Uses

    Helps control blood sugar in adults with type 2 diabetes (when prescribed).
    Intended to assist adults with weight loss as directed by a healthcare provider.

  • Warnings — Read carefully and tell your doctor if any apply to you.

    Pancreatitis: Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.
    Allergic reaction: Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.
    Serious gastrointestinal disease: May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).
    Acute gallbladder disease: Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.
    Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.
    Pregnancy or breastfeeding: Do not use.
    Children: Do not use.

    Drug Interactions / Precautions

    Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.
    Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.
    Cardiovascular medications: Caution with statins, digoxin, or warfarin.

    Statins: absorption may be affected; monitor lipid levels.
    Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

    General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

    Possible side effects

    Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.

    When to stop and call your doctor

    If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

  • Directions — Preparation & Dosing (basic patient summary)

    Concentration after reconstitution (calculation):

    10 mg ÷ 1 mL = 10 mg/mL.
    Therefore: 0.25 mL = 2.5 mg; 0.5 mL = 5 mg; 0.75 mL = 7.5 mg; 1 mL = 10 mg.

    Typical weekly dosing schedule (example shown — follow your prescriber):

    Weeks 1–4: 0.25 mL (2.5 mg) once weekly (subcutaneous)
    Weeks 5–8: 0.5 mL (5 mg) once weekly
    Weeks 9–12: 0.75 mL (7.5 mg) once weekly
    Week 13 and onward: 1 mL (10 mg) once weekly

    One carton (4 kits) provides 4 weekly doses.

    How to prepare and inject (patient summary):

    Wash hands with soap and water. Inspect vials for damage.
    Using aseptic technique, withdraw the prescribed volume (in mL) of Sterile Water for Injection into a sterile syringe. Inject the diluent into the vial containing the lyophilized powder.
    Gently swirl the vial until the powder fully dissolves. Do not shake vigorously. Solution should be clear; do not use if cloudy or particulate present.
    Withdraw the prescribed volume (e.g., 0.25, 0.5, 0.75 or 1 mL) into a sterile syringe and inject subcutaneously in the abdomen, thigh, or upper arm after cleaning the site with alcohol. Rotate injection sites.
    Dispose of syringe/needle in an appropriate sharps container.

  • Do not use

    Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.
    Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.
    Cardiovascular medications: Caution with statins, digoxin, or warfarin.

    Statins: absorption may be affected; monitor lipid levels.
    Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

    General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

  • When using section

    Pancreatitis: Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.
    Allergic reaction: Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.
    Serious gastrointestinal disease: May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).
    Acute gallbladder disease: Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.
    Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.
    Pregnancy or breastfeeding: Do not use.
    Children: Do not use.

    Drug Interactions / Precautions

    Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.
    Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.
    Cardiovascular medications: Caution with statins, digoxin, or warfarin.

    Statins: absorption may be affected; monitor lipid levels.
    Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

    General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

    Possible side effects

    Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.

    When to stop and call your doctor

    If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

  • stop use

    Pancreatitis: Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.
    Allergic reaction: Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.
    Serious gastrointestinal disease: May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).
    Acute gallbladder disease: Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.
    Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.
    Pregnancy or breastfeeding: Do not use.
    Children: Do not use.

    Drug Interactions / Precautions

    Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.
    Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.
    Cardiovascular medications: Caution with statins, digoxin, or warfarin.

    Statins: absorption may be affected; monitor lipid levels.
    Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

    General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

    Possible side effects

    Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.

    When to stop and call your doctor

    If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

  • Keep out of reach of children.

    Not for use in children.

  • Inactive Ingredients:

    Mannitol, Disodium Hydrogen Phosphate, Sodium Dihydrogen Phosphate, Sodium Chloride, Sodium Bicarbonate.

  • PRINCIPAL DISPLAY PANEL

    01020304

  • INGREDIENTS AND APPEARANCE
    SALKALLI 
    retatrutide lyophilized powder injection, powder, lyophilized, for solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:84778-110
    Route of AdministrationSUBCUTANEOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    RETATRUTIDE (UNII: NOP2Y096GV) (RETATRUTIDE - UNII:NOP2Y096GV) RETATRUTIDE2.5 mg  in 0.25 mL
    Inactive Ingredients
    Ingredient NameStrength
    SODIUM BICARBONATE (UNII: 8MDF5V39QO)  
    MANNITOL (UNII: 3OWL53L36A)  
    SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORM (UNII: 3980JIH2SW)  
    SODIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: 22ADO53M6F)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:84778-110-062 in 1 PACKAGE, COMBINATION10/30/2025
    14 in 1 CARTON
    10.25 mL in 1 KIT; Type 1: Convenience Kit of Co-Package
    2NDC:84778-110-054 in 1 CARTON10/30/2025
    20.25 mL in 1 KIT; Type 1: Convenience Kit of Co-Package
    3NDC:84778-110-073 in 1 PACKAGE, COMBINATION10/30/2025
    34 in 1 CARTON
    30.25 mL in 1 KIT; Type 1: Convenience Kit of Co-Package
    4NDC:84778-110-084 in 1 PACKAGE, COMBINATION10/30/2025
    44 in 1 CARTON
    40.25 mL in 1 KIT; Type 1: Convenience Kit of Co-Package
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Export only10/30/2025
    Labeler - Guangzhou Yixin Cross-border E-commerce Co., Ltd. (455800881)
    Registrant - Guangzhou Yixin Cross-border E-commerce Co., Ltd. (455800881)
    Establishment
    NameAddressID/FEIBusiness Operations
    Guangzhou Yixin Cross-border E-commerce Co., Ltd.455800881label(84778-110) , manufacture(84778-110)